Patents by Inventor Suanne Nakajima

Suanne Nakajima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
    Patent number: 8236807
    Abstract: The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: July 20, 2009
    Date of Patent: August 7, 2012
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Suanne Nakajima, Zhenwei Miao, Ying Sun, Datong Tang, Guoyou Xu, Brian Porter, Yat Sun Or, Zhe Wang
  • Macrocyclic hepatitis C serine protease inhibitors
    Patent number: 8124584
    Abstract: The present invention relates to compounds of Formula I, II or III, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: February 28, 2012
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Zhenwei Miao, Ying Sun, Suanne Nakajima, Datong Tang, Frank Wu, Guoyou Xu, Yat Sun Or, Zhe Wang
  • Tri-peptide hepatitis C serine protease inhibitors
    Patent number: 7718769
    Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: November 20, 2006
    Date of Patent: May 18, 2010
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Zhenwei Miao, Ying Sun, Suanne Nakajima, Datong Tang, Zhe Wang, Yat Sun Or
  • 6-11 Bridged Oxime Erythromycin Derivatives
    Publication number: 20100041618
    Abstract: The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes processes by which to make the compounds of the present invention.
    Type: Application
    Filed: August 18, 2009
    Publication date: February 18, 2010
    Inventors: Guoqiang Wang, Ly Tam Phan, Yat Sun Or, Yao-Ling Qiu, Deqiang Niu, Yulin Peng, Marina Busuyek, Yanchun Wang, Suanne Nakajima
  • QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
    Publication number: 20100015092
    Abstract: The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: July 20, 2009
    Publication date: January 21, 2010
    Inventors: Suanne Nakajima, Zhenwei Miao, Ying Sun, Datong Tang, Guoyou Xu, Brian Porter, Yat Sun Or, Zhe Wang
  • MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
    Publication number: 20090304629
    Abstract: The present invention relates to compounds of Formula I, II or III, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: January 9, 2009
    Publication date: December 10, 2009
    Inventors: Zhenwei Miao, Ying Sun, Suanne Nakajima, Datong Tang, Frank Wu, Guoyou Xu, Yat S. Or, Zhe Wang
  • Macrocyclic hepatitis C serine protease inhibitors
    Patent number: 7601709
    Abstract: The present invention relates to compounds of Formula I, II or Ill, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: February 6, 2004
    Date of Patent: October 13, 2009
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Zhenwei Miao, Ying Sun, Suanne Nakajima, Datong Tang, Frank Wu, Guoyou Xu, Yat S. Or, Zhe Wang
  • Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
    Patent number: 7566719
    Abstract: The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: March 6, 2008
    Date of Patent: July 28, 2009
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Suanne Nakajima, Zhenwei Miao, Ying Sun, Datong Tang, Guoyou Xu, Brian Porter, Yat Sun Or, Zhe Wang
  • 6-11 Bridged Oxime Erythromycin Derivatives
    Publication number: 20080262208
    Abstract: The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes processes by which to make the compounds of the present invention.
    Type: Application
    Filed: May 20, 2008
    Publication date: October 23, 2008
    Inventors: Guoqiang Wang, Ly Tam Phan, Yat Sun Or, Yao-Ling Qiu, Deqiang Niu, Yulin Peng, Marina Busuyek, Yanchun Wang, Suanne Nakajima
  • QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
    Publication number: 20080152622
    Abstract: The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: March 6, 2008
    Publication date: June 26, 2008
    Inventors: Suanne Nakajima, Zhenwei Miao, Ying Sun, Datong Tang, Guoyou Xu, Brian Porter, Yat Sun Or, Zhe Wang
  • Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
    Patent number: 7368452
    Abstract: The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: July 18, 2006
    Date of Patent: May 6, 2008
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Suanne Nakajima, Zhenwei Miao, Ying Sun, Datong Tang, Gouyou Xu, Brian Porter, Yat Sun Or, Zhe Wang
  • Tri-peptide hepatitis C serine protease inhibitors
    Patent number: 7273851
    Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: May 19, 2004
    Date of Patent: September 25, 2007
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Zhenwei Miao, Ying Sun, Suanne Nakajima, Datong Tang, Zhe Wang, Yat S. Or
  • Tri-peptide hepatitis C serine protease inhibitors
    Publication number: 20070161575
    Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: November 20, 2006
    Publication date: July 12, 2007
    Applicant: Enanta Pharmaceuticals, Inc.
    Inventors: Zhenwei Miao, Ying Sun, Suanne Nakajima, Datong Tang, Zhe Wang, Yat Or
  • Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
    Publication number: 20070060510
    Abstract: The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: July 18, 2006
    Publication date: March 15, 2007
    Applicant: Enanta Pharmaceuticals, Inc.
    Inventors: Suanne Nakajima, Zhenwei Miao, Ying Sun, Datong Tang, Guoyou Xu, Brian Porter, Yat Or, Zhe Wang
  • Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
    Patent number: 7176208
    Abstract: The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: April 16, 2004
    Date of Patent: February 13, 2007
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Suanne Nakajima, Zhenwei Miao, Ying Sun, Datong Tang, Guoyou Xu, Brian Porter, Yat Sun Or, Zhe Wang
  • Aza-peptide macrocyclic hepatitis c serine protease inhibitors
    Publication number: 20070021330
    Abstract: The present invention relates to compounds of Formula (I), or a pharmaceutically acceptable salt, ester, or prodrug, thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: May 19, 2004
    Publication date: January 25, 2007
    Applicant: Enanta Pharmaceuticals, Inc.
    Inventors: Frank Wu, Suanne Nakajima, Yat Or, Zhi-Hui Lu, Ying Sun, Zhenwei Miao, Zhe Wang
  • 6-11 Bridged oxime erythromycin derivatives
    Publication number: 20060252712
    Abstract: The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes processes by which to make the compounds of the present invention.
    Type: Application
    Filed: May 3, 2006
    Publication date: November 9, 2006
    Inventors: Guoqiang Wang, Ly Phan, Yat Or, Yao-ling Qiu, Deqiang Niu, Yulin Peng, Marina Busuyek, Yanchun Wang, Suanne Nakajima
  • 6-11 Bridged oxime erythromycin derivatives
    Publication number: 20060252710
    Abstract: The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes processes by which to make the compounds of the present invention.
    Type: Application
    Filed: May 4, 2005
    Publication date: November 9, 2006
    Inventors: Guoqiang Wang, Ly Phan, Yat Or, Yao-Ling Qiu, Deqiang Niu, Yulin Peng, Marina Busuyek, Yanchun Wang, Suanne Nakajima
  • Aza-peptide macrocyclic hepatitis C serine protease inhibitors
    Patent number: 7125845
    Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: July 3, 2003
    Date of Patent: October 24, 2006
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Frank X. H. Wu, Suanne Nakajima, Zhi-Hui Lu, Ying Sun, Zhenwei Miao, Yat Sun Or, Zhe Wang
  • Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
    Patent number: RE42375
    Abstract: The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: February 11, 2008
    Date of Patent: May 17, 2011
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Suanne Nakajima, Zhenwei Miao, Ying Sun, Datong Tang, Guoyou Xu, Brian Porter, Yat Sun Or, Zhe Wang